Portal login

One Blood Draw. Three Scores. Clear Clinical Answers.

Blood-based liver assessment designed for screening, identification, staging, and monitoring of MASLD/MASH patients.​

What It Does

What does LIVERFASt™ measure?

Fibrosis
The accumulation of thick bands of scar tissue (collagen) in the liver
Activity
The level of inflammation and cellular damage occurring within the liver
Steatosis
The accumulation of excess fat (mostly triglycerides) inside liver cells
LIVERFASt report

Transforming liver care with simple, accurate, and actionable insights. Join the leading healthcare providers using LiverFast to find the invisible patients today.

Connect with our experts
Why It Matters

Designed for Real-World Liver Care Our 5 Key Advantage

Screening

Rule out low-risk patients confidently​

Identification

Find “invisible” at-risk patients earlier​

Monitoring

Track fibrosis, steatosis, and activity longitudinally​

Clinical Pathway

Works effectively with FibroScan/VCTE​

Ease of Use

Simple blood test using common biomarkers

How to order

Physician prescribes LIVERFASt

Lab analyzes 10 biomarkers from 1 blood sample

Biomarker values plus age, height, weight and gender entered into platform

LIVERFASt results
available immediately

Download test form
WHY LIVERFASt vs FIB-4

Find more. Miss less!

LIVERFASt™

  • No gray zone
  • Higher sensitivity
  • Clear staging
  • Actionable results
  • 65.5% sensivity
  • 2x more advanced fibrosis cases identified
  • NPV > 99.5%

FIB-4

  • Grey zone
  • Lower sensitivity
  • Less stratification clarity
  • Indeterminate patients
  • 37.3% sensitivity
Screening brochure
Clinical Pathway

Superior 2-step NIT clinical pathway

LIVERFASt followed by Fibroscan finds more patients, increases certainty and decreases churn.

Stratify patient risk
Prioritize specialist referrals
Reduce unnecessary procedures
Optimize use of diagnostic resources

Win for PCPS

Safely rules-out F0-F1 patients with certainty. Identifies more ≥F2 patients with greater certainty

Win for Patients

An easy to do test with results that are clear and actionable

Win for Specialists

More and better qualified ≥F2 patients, more likely to be confirmed by VCTE
Clinical Pathway Brochure​
Use Cases

Clinical use cases

Primary Care Screening​

Identify low-risk vs at-risk patients​

Specialist Referral​

Better qualified referrals

Longitudinal Monitoring​

Track changes over time​

Clinical Trials / Pharma​

Structured patient stratification​

Monitoring

Designed for Longitudinal Monitoring

Fibrosis 
Monitoring

Delivers 65.5% sensitivity for advanced fibrosis (≥ F3), nearly doubling the accuracy of FIB-4. Safely rules out low-risk patients while identifying advanced scarring early.

Steatosis Monitoring

Identifies early-stage fatty liver accumulation to establish a non-invasive baseline, allowing continuous tracking of fat build-up before structural damage occurs.

Activity Monitoring

Tracks real-time liver tissue inflammation and disease severity. Integrates seamlessly with VCTE (Fibroscan) to provide a 90% concordance rate for confident clinical decisions.

Repeatable Blood-Based Testing

Tracks patient response to treatment in real time through simple, repeatable blood tests, providing clear and actionable monitoring over time.

No Specialised Imaging Dependency

Eliminates the need for specialized imaging equipment by utilizing common serum biomarkers. Reduces clinical costs and unnecessary procedures while maintaining high accuracy.
Monitoring brochure

Identification and Performance

Closing the Gap: Clinically Validated Discovery of Hidden Patients

Identifying who are the hidden patients early
High-risk populations​
T2D
Obesity
BMI > 30
Cardiometabolic disease
Clinically validated performance
AUROC
Sensitivity
NPV
Comparison vs FIB-4
VCTE concordance

Bring clearer answers to liver care

Contact our sales representative to inquire more about LIVERFASt™ and how it can help you and your patients improve their liver health.

Contact us today